London and New Jersey-based cell and gene therapy (CGT) manufacturing technology firm Ori Biotech aims to accelerate CGT manufacturing processes. The company was highlighted on our recent roundup of prominent cell and gene therapy vendors in 2023.
In January 2022, the company secured more than $100 million in a Series B funding round, enabling the move from pre-commercialization to market launch. According to CEO Jason C. Foster, the company has grown from “three of us in the biotech equivalent of a garage” to 72 employees and raised $140 million in venture funding to date.From investor to CEO of Ori Biotech
Foster met the Ori team in 2018, working with them as an investor. He later joined full time as CEO after the company closed its first institutional round in 2019.
Ori Biotech has developed a proprietary platform that automates and standardizes CGT manufact…